Octapharma AG
Trending Articles
Related Content
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
BAC and Octapharma extend recombinant Factor IX collaboration
<p>BAC, a Dutch provider of antibody-based affinity purification technology, has signed a licence agreement with Octapharma, a Swiss biopharmaceutical company, to use BAC's anti-Factor IX CaptureSelect affinity ligand in the large-scale purification of recombinant Factor IX (FIX). </p>